NEW YORK, October 11, 2021 / PRNewswire / – WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Adamas Pharmaceuticals, Inc. (“Adamas” or the “Company”) ( NASDAQ: ADMS) in connection with the proposed acquisition of the Company by Supernus Pharmaceuticals, Inc. (“Supernus”) (NASDAQ: SUPN), via a takeover bid. Under the terms of the Merger Agreement, the shareholders of the Company will receive $ 8.10 per share in cash payable at closing, plus two non-negotiable conditional value rights with a collective value of up to $ 1.00 per share in cash, payable upon reaching certain thresholds for net sales of the Company’s flagship product, GOCOVRI, for each Adamas ordinary share they hold.
If you have Adamas shares and would like to discuss this survey or if you have any questions regarding this notice or your rights or interests, visit our website:
Or please contact:
Joshua Rubin, Esq.
305 Broadway, 7e Ground
new York, NY 10007
WeissLaw LLP is considering whether (i) the board of directors of Adamas has acted in the best interests of the shareholders of the Company in accepting the proposed transaction, (ii) the $ 8.10 the offer price per share adequately remunerates the shareholders of Adamas, and (iii) all information regarding the sale process and the valuation of the transaction will be disclosed in a full and fair manner. In particular, the merger consideration is lower than the $ 9.00 median price targets set by analysts following the Company and at least one analyst has set a price target for the Company of $ 14 per share, $ 5.90 above the merger price per share.
WeissLaw LLP has litigated hundreds of class and derivative shareholder actions for breach of corporate and fiduciary obligations. We have recovered over $ 1 billion for defrauded clients and obtained significant corporate governance relief in many of these cases. If you have information or want legal advice regarding possible corporate wrongdoing (including insider trading, waste of company assets, accounting fraud or misleading information), fraud consumer (including misleading advertising, defective products, or other deceptive marketing practices), or violations of antitrust laws, please email us at [email protected]
SOURCE WeissLaw LLP